Re:When the Patient Is a Gold Mine: The Trouble with Rare-Di...
by tuna-piano on Wednesday May 24, 2017 @08:09PM
(#14414419)
While the math isn't exactly right - even if Alexion returned all profits to its patients at the end of the year, the cost of the drug would still be only 20% less than the current price. So instead of $500k, it would be $400k. Would that really change the dynamics of the discussion?
[ Parent
| on HN ]
Re:When the Patient Is a Gold Mine: The Trouble with Rare-Di...
by refurb on Wednesday May 24, 2017 @09:38PM
(#14414749)
Great point to call out. Also, Alexion uses about 21% of their revenue for R&D. So of the $500K they sell the product for, $100K is profit, $100K goes back into R&D and the rest is paying for expenses.